{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:37:26Z","timestamp":1786718246473,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oman J Ophthalmol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/ojo.ojo_232_2014","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T02:50:17Z","timestamp":1507171817000},"page":"145","source":"Crossref","is-referenced-by-count":17,"title":["Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis"],"prefix":"10.4103","volume":"10","author":[{"given":"AbdulrahmanMohammed","family":"Al-Amri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SandraFlavia","family":"Fiorentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MaanA","family":"Albarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AshjanYousef","family":"Bamahfouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0974-620X.216005-1","first-page":"1019","volume-title":"Allergic and immunologic disorders of the eye.Part II: Ocular allergy","author":"Bielory","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/0974-620X.216005-2","first-page":"354","volume-title":"Basic sciences in clinical glaucoma: Steroids, ocular hypertension, and glaucoma","author":"Clark","year":"1995","journal-title":"J Glaucoma"},{"key":"key-10.4103\/0974-620X.216005-3","unstructured":"Tabbara AK, El-Asrar A. Immunopathogenesis of ocular allergy. Progress in Allergy and Clinical Immunology. Seattle: Hogrefe & Huber; 1997. p. 381-5."},{"key":"key-10.4103\/0974-620X.216005-4","first-page":"557","volume-title":"Development and testing of the quality of life in children with vernal keratoconjunctivitis questionnaire","author":"Sacchetti","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0974-620X.216005-5","first-page":"319","volume-title":"Vernal keratoconjunctivitis: Pathogenesis and treatment","author":"Leonardi","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"key-10.4103\/0974-620X.216005-6","first-page":"455","volume-title":"Ocular allergic disease","author":"Stahl","year":"2004","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"key-10.4103\/0974-620X.216005-7","first-page":"1157","volume-title":"Vernal keratoconjunctivitis revisited: A case series of 195 patients with long-term followup","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"key-10.4103\/0974-620X.216005-8","first-page":"357","volume-title":"05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children","author":"Keklikci","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.4103\/0974-620X.216005-9","first-page":"455","volume-title":"Topical cyclosporine a 0.05% eyedrops in the treatment of vernal keratoconjunctivitis - Randomized placebo-controlled trial","author":"Keklikci","year":"2014","journal-title":"Adv Clin Exp Med"},{"key":"key-10.4103\/0974-620X.216005-10","first-page":"73","volume-title":"Management of vernal keratoconjunctivitis","author":"Leonardi","year":"2013","journal-title":"Ophthalmol Ther"},{"key":"key-10.4103\/0974-620X.216005-11","unstructured":"William F. Ganong. Review of medical physiology. 22nd ed. Lange Medical Books. 2005. p. 530"},{"key":"key-10.4103\/0974-620X.216005-12","first-page":"634","volume-title":"Cyclosporine vs.tacrolimus therapy for posterior and intermediate uveitis","author":"Murphy","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"key-10.4103\/0974-620X.216005-13","first-page":"746","volume-title":"Tacrolimus.A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation","author":"Peters","year":"1993","journal-title":"Drugs"},{"key":"key-10.4103\/0974-620X.216005-14","first-page":"1219","volume-title":"Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system.(Comparison with steroids)","author":"Sakuma","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"key-10.4103\/0974-620X.216005-15","first-page":"89","volume-title":"Tacrolimus in the treatment of ocular diseases","author":"Zhai","year":"2011","journal-title":"BioDrugs"},{"key":"key-10.4103\/0974-620X.216005-16","first-page":"280","volume-title":"Long-term follow-up of tacrolimus of ointment for treatment atopic keratoconjunctivitis","author":"Al-Amri","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0974-620X.216005-17","first-page":"417","volume-title":"Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders","author":"Joseph","year":"2005","journal-title":"Cornea"},{"key":"key-10.4103\/0974-620X.216005-18","first-page":"228","volume-title":"Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis","author":"Kymionis","year":"2008","journal-title":"Cornea"},{"key":"key-10.4103\/0974-620X.216005-19","doi-asserted-by":"crossref","unstructured":"Mayer K, Reinhard T, Reis A, B\u00f6hringer D, Sundmacher R. FK 506 ointment 0.1% - A new therapeutic option for atopic blepharitis. Clinical trial with 14 patients. Klin Monbl Augenheilkd 2001;218:733-6.","DOI":"10.1055\/s-2001-18665"},{"key":"key-10.4103\/0974-620X.216005-20","doi-asserted-by":"crossref","unstructured":"Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, Nagata Y, Hasegawa J, Inoue Y. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008;115:988-92.e5.","DOI":"10.1016\/j.ophtha.2007.07.025"},{"key":"key-10.4103\/0974-620X.216005-21","first-page":"165","volume-title":"A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis","author":"Ohashi","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.4103\/0974-620X.216005-22","first-page":"1405","volume-title":"Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis - Case series","author":"Tam","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key-10.4103\/0974-620X.216005-23","first-page":"804","volume-title":"Application for tacrolimus ointment in treating refractory inflammatory ocular surface diseases","author":"Lee","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"key-10.4103\/0974-620X.216005-24","first-page":"872","volume-title":"Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis","author":"Kheirkhah","year":"2011","journal-title":"Eye (Lond)"},{"key":"key-10.4103\/0974-620X.216005-25","first-page":"1147","volume-title":"Systemic tacrolimus in the treatment of severe atopic keratoconjunctivitis","author":"Stumpf","year":"2006","journal-title":"Cornea"},{"key":"key-10.4103\/0974-620X.216005-26","first-page":"1956","volume-title":"Association between exposure to topical tacrolimus or pimecrolimus and cancers","author":"Hui","year":"2009","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/0974-620X.216005-27","first-page":"465","volume-title":"Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors","author":"Tennis","year":"2011","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0974-620X.216005-28","first-page":"275","volume-title":"Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% tacrolimus ophthalmic suspension","author":"Ebihara","year":"2012","journal-title":"Allergol Int"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:32:51Z","timestamp":1786714371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.OJO_232_2014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"alternative-id":["216005"],"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_232_2014","relation":{},"ISSN":["0974-620X"],"issn-type":[{"value":"0974-620X","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}